BCAB Stock Overview
A clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
BioAtla, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.48 |
| 52 Week High | US$4.02 |
| 52 Week Low | US$1.14 |
| Beta | 1.02 |
| 11 Month Change | -24.10% |
| 3 Month Change | -17.78% |
| 1 Year Change | -8.07% |
| 33 Year Change | -94.24% |
| 5 Year Change | n/a |
| Change since IPO | -95.23% |
Recent News & Updates
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
Oct 08We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate
Jul 16
Recent updates
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
Oct 08We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate
Jul 16BioAtla: A Buried ADC Concern Gets Some New Life In 2024
May 02Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 14Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?
Nov 05We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
Jun 27Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 24BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Sep 27BioAtla: Back From The Dead
Sep 23BioAtla: Promising Signal In NSCLC, But Concerns Remain
Aug 23BioAtla reports Q2 results
Aug 09We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate
May 11Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth
Jan 06BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Jul 24Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?
Mar 16Shareholder Returns
| BCAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -25.6% | -7.5% | -1.2% |
| 1Y | -8.1% | 14.1% | 30.4% |
Return vs Industry: BCAB underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: BCAB underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| BCAB volatility | |
|---|---|
| BCAB Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCAB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BCAB's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 65 | Jay Short | www.bioatla.com |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.
BioAtla, Inc. Fundamentals Summary
| BCAB fundamental statistics | |
|---|---|
| Market cap | US$72.52m |
| Earnings (TTM) | -US$81.82m |
| Revenue (TTM) | US$11.00m |
6.5x
P/S Ratio-0.9x
P/E RatioIs BCAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCAB income statement (TTM) | |
|---|---|
| Revenue | US$11.00m |
| Cost of Revenue | US$74.12m |
| Gross Profit | -US$63.12m |
| Other Expenses | US$18.70m |
| Earnings | -US$81.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | -573.81% |
| Net Profit Margin | -743.79% |
| Debt/Equity Ratio | 0% |
How did BCAB perform over the long term?
See historical performance and comparison